Reneo Pharmaceuticals RPHM, a clinical-stage company, announced the failure of the mid-stage pivotal STRIDE study of its investigational candidate, mavodelpar (REN001), to treat primary mitochondrial ...
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Reneo Pharmaceuticals Inc (NASDAQ:RPHM) anticipates pivotal STRIDE study topline data in December 2023. Q3 2023 saw a net loss of $19.2 million, a deeper loss compared to Q3 2022's $13.0 million.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) and OnKure, Inc. is fair to Reneo ...
In a report released on March 31, Joseph Schwartz from SVB Securities reiterated a Buy rating on Reneo Pharmaceuticals (RPHM – Research Report), with a price target of $15.00. The company’s shares ...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (RPHM) (“Reneo”) with privately held OnKure, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results